-
公开(公告)号:US20190022243A1
公开(公告)日:2019-01-24
申请号:US16069395
申请日:2017-01-13
Applicant: GENMAB A/S
Inventor: Julia BOSHUIZEN , Esther BREIJ , Louise KOOPMAN , David SATIJN , Edward VAN DEN BRINK , Dennis VERZIJL , Rob DE JONG , Riemke VAN DIJKHUIZEN RADERSMA , Daniel PEEPER , Paul PARREN
Abstract: Antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of melanoma in combination with one or more MAPK pathway inhibitors such as, e.g., a BRAF inhibitor and/or a MEK inhibitor.
-
公开(公告)号:US20230321261A1
公开(公告)日:2023-10-12
申请号:US17957302
申请日:2022-09-30
Applicant: GENMAB A/S
Inventor: Julia BOSHUIZEN , Esther BREIJ , Louise KOOPMAN , David SATIJN , Edward VAN DEN BRINK , Dennis VERZIJL , Rob DE JONG , Riemke VAN DIJKHUIZEN RADERSMA , Daniel PEEPER , Paul PARREN
CPC classification number: A61K47/6803 , A61K39/001102 , A61K45/06 , A61K47/6801 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6857 , A61K47/6869 , A61P35/00 , C07K16/2863 , A61K2039/505 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/732 , C07K2317/77 , C07K2317/92
Abstract: Antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of melanoma in combination with one or more MAPK pathway inhibitors such as, e.g., a BRAF inhibitor and/or a MEK inhibitor.
-
公开(公告)号:US20210070869A1
公开(公告)日:2021-03-11
申请号:US17046199
申请日:2019-04-10
Applicant: GENMAB A/S
Inventor: Maarten JANMAAT , Esther BREIJ , Ulf FORSSMANN , Tahamtan AHMADI , Julia BOSHUIZEN , Daniel PEEPER , Nora PENCHEVA
Abstract: The disclosure relates to anti-AXL antibodies, immunoconjugates, and compositions for treatment of cancer, which is resistant to or is predicted to be or become resistant to treatment with a programmed cell death-1/programmed cell death-1 ligand (PD-1/PD-L1) inhibitor.
-
公开(公告)号:US20180326084A1
公开(公告)日:2018-11-15
申请号:US15742818
申请日:2016-07-08
Applicant: GENMAB A/S
Inventor: Julia BOSHUIZEN , Kirstine JACOBSEN , Esther BREIJ , Louise KOOPMAN , David SATIJN , Edward VAN DEN BRINK , Dennis VERZIJL , Rob DE JONG , Riemke VAN DIJKHUIZEN RADERSMA , Daniel PEEPER , Henrik Jørn DITZEL , Paul PARREN
CPC classification number: A61K47/6803 , A61K39/001102 , A61K45/06 , A61K47/6801 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6857 , A61K47/6869 , A61K2039/505 , A61P35/00 , C07K16/2863 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/732 , C07K2317/77 , C07K2317/92
Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of resistant or refractory cancers.
-
-
-